F. ISIS-2, 1988
This landmark study is the first to show the remarkable benefits of aspirin when given immediately following the onset of chest pain caused by myocardial infarction. The second International Study of Infarct Survival (ISIS-2), a study mounted in the UK, confirmed a marked increase in survival in a large group of patients given 160 mg of plain aspirin (noncoated) within 6 h of the onset of chest pain causing a heart attack. In that study, aspirin greatly improved the life-saving effects of strepto-kinase, a drug used to dissolve clots soon after the occur¬rence of a heart attack.
G. Primary Prevention, 1988
Finally, in 1988, a trial with 22,071 male U.S. physicians aged 40–84 given 325 mg of aspirin on alternate days for five years demonstrated that aspirin use resulted in a 44% reduction in the risk of nonfatal myocardial
infarction. This trial endorsed the use of small-dose coated aspirin preparations in normal individuals deemed at risk for coronary artery disease and its complications.
H. Swedish Trial, 1992
The Swedish angina pectoris aspirin trial studied 2035 patients with chronic stable angina without infarction. Aspirin, 75 mg, reduced the occurrence of infarction and sudden death by 34% in the treated patients versus placebo.

Страницы: 1 | 2 | 3